SCHEMBL14952425

SCHEMBL14952425

C[C@@H]1C(=O)Nc2cnc(Cl)nc2N1C1CCC(F)(F)CC1

nearest known ligand 0.33

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RPS6KA3 P51812 1/20 0.33
▸ PDE9A O76083 5/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ BRD4 O60885 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ PLK1 P53350 1/20 0.30
▸ PLK3 Q9H4B4 1/20 0.30
▸ PLK2 Q9NYY3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3231088 0.88 PLK1 (0.37) RPS6KA3KDM4EMEN1ALDH1A1MAPT
SCHEMBL3231101 0.88 PLK1 (0.37) RPS6KA3KDM4EMEN1ALDH1A1MAPT
SCHEMBL31098116 0.87 PLK1 (0.36) RPS6KA3PDE9AKDM4EMEN1ALDH1A1
SCHEMBL14952424 0.87 PLK1 (0.36) RPS6KA3PDE9AKDM4EMEN1ALDH1A1
SCHEMBL14952220 0.82 CNR2 (0.33) RPS6KA3KDM4EMEN1ALDH1A1MAPT
SCHEMBL2542429 0.79 PLK1 (0.42) BRD4PLK1PLK3PLK2
SCHEMBL2542430 0.79 PLK1 (0.42) BRD4PLK1PLK3PLK2
SCHEMBL4076299 0.78 KDM4E (0.33) KDM4EMEN1ALDH1A1MAPTHPGD
SCHEMBL4083751 0.76 PLK1 (0.36) KDM4EMEN1ALDH1A1MAPTHPGD
SCHEMBL5936768 0.75 PLK1 (0.46) KDM4EMEN1ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9351974-B2 Substituted pteridinones for the treatment of cancer OSI Pharmaceuticals, LLC (US) 2016-05-31 — — US disclosed
US-9351974-B2 Substituted pteridinones for the treatment of cancer OSI Pharmaceuticals, LLC (US) 2016-05-31 — — US disclosed
US-20140315911-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC 2014-10-23 — — US disclosed
US-20140315911-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC 2014-10-23 — — US disclosed
WO-2013071217-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC (US) 2013-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315911-A1 DIHYDROPTERIDINONES DHPS, DHODH, HYPK RPS6KA3 62/4885PDE9A 4831/4885PARP1 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback